<DOC>
	<DOCNO>NCT00000695</DOCNO>
	<brief_summary>To determine high tolerate dose safety tolerance interferon beta ( IFN-B ) give time zidovudine ( AZT ) patient early AIDS relate Kaposi 's sarcoma . In addition , study determine preliminary data response , immune function , subcutaneous absorption . IFN-B demonstrated dose-dependent ability suppress replication HIV test tube . In addition , previous study show AZT effective inhibitor HIV reverse transcriptase ; Phase I II study benefit AZT treatment include increase objective clinical improvement , decrease mortality rate , decrease incidence opportunistic infection . Long-term AZT use , however , present possible limitation secondary intolerance . This study , therefore , investigate potential antiviral activity combination IFN-B AZT determine safety efficacy treatment patient AIDS relate Kaposi 's sarcoma . It believe combination drug therapy consist low dos drug reduce potential toxicity , treatment failure , disease recurrence result drug-resistant virus mutant .</brief_summary>
	<brief_title>Open Label Phase I Study To Evaluate Safety Combination Therapy With AZT Interferon-Beta Patients With AIDS Related Kaposi 's Sarcoma</brief_title>
	<detailed_description>IFN-B demonstrate dose-dependent ability suppress replication HIV test tube . In addition , previous study show AZT effective inhibitor HIV reverse transcriptase ; Phase I II study benefit AZT treatment include increase objective clinical improvement , decrease mortality rate , decrease incidence opportunistic infection . Long-term AZT use , however , present possible limitation secondary intolerance . This study , therefore , investigate potential antiviral activity combination IFN-B AZT determine safety efficacy treatment patient AIDS relate Kaposi 's sarcoma . It believe combination drug therapy consist low dos drug reduce potential toxicity , treatment failure , disease recurrence result drug-resistant virus mutant . Patients undergo evaluation determine extent disease status immune system . Patients receive IFN-B subcutaneously day one three different dose level . Patients also take AZT 1 2 dos . The first 12 patient treat low dose AZT . The first 4 patient enter level 1 IFN-B . If dose-limiting toxicity see 4 patient 2 week therapy , 4 patient enrol level 2 IFN-B . The study proceeds manner high tolerate dose level 3 reach . If drug tolerate , patient remain medication long continue tolerate medication show improvement either antiviral response , immune response , clinical response long 24 week . The initial three dose IFN-B give patient study site time patient trained self-administer IFN-B . Patients see weekly 4 month every 2 week thereafter .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Inclusion Criteria Concurrent Treatment : Allowed : Local radiotherapy laser therapy cosmetically apparent Kaposi 's lesion , provide dose one lesion exceed 3000 gray total surface area lesion treat exceed 10 cm2 course trial . Patients must demonstrate follow clinical laboratory finding : Positive HIV federally license ELISA test . Acceptable bone marrow function . Acceptable renal function . Acceptable hepatic function . Exclusion Criteria Concurrent Medication : Excluded : Other potentially antiretroviral compound . Patients exclude study follow reason : Concurrent , active opportunistic infection require therapy . Extensive Kaposi 's sarcoma 100 cutaneous lesion , require systemic chemotherapy , prior treatment one chemotherapy regimen , exclude intralesional therapy , symptomatic visceral Kaposi 's sarcoma . Evidence clinically significant cardiac dysfunction ( New York Heart Association grade III IV ) . History malignant neoplasms nonmelanomatous skin cancer cancer situ cervix . Proteinuria 2+ great and/or 24hour urine protein great 1 . Prior Medication : Excluded : More one chemotherapy regimen Kaposi 's sarcoma . Any interferon preparation zidovudine ( AZT ) . Excluded within 30 day study entry : Other immunomodifiers . Acyclovir . Other investigational drug . Excluded within 60 day study entry : Cytotoxic therapy . Patients may follow disease symptom : Development AIDSdefining opportunistic infection , oral thrush localize zoster . NonKaposi 's sarcoma , AIDSdefining malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Interferon Type I</keyword>
</DOC>